These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27613064)

  • 1. Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
    Kalra S
    Diabetes Ther; 2016 Dec; 7(4):601-609. PubMed ID: 27613064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
    Suissa S
    Diabetes Care; 2018 Feb; 41(2):219-223. PubMed ID: 29358464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons From LEADER - All-round Leadership.
    Kalra S
    Eur Endocrinol; 2016 Aug; 12(2):76-78. PubMed ID: 29632591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    Arbel R; Hammerman A; Azuri J
    Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.
    Kalra S; Sahay R
    Indian J Endocrinol Metab; 2017; 21(1):245-248. PubMed ID: 28217527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
    Schatz H
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):459-460. PubMed ID: 27701709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D; Meier JJ; Esposito K
    Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.
    Madievsky R
    Perm J; 2018; 22():18-034. PubMed ID: 30227909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.
    Hinton W; Feher M; Munro N; de Lusignan S
    Diabetes Ther; 2018 Jun; 9(3):1397-1402. PubMed ID: 29605893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    Rossello X; Yellon DM
    Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Scheen AJ; Wallemacq C; Jandrain B; Ernest P
    Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ; Marx N
    Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.